key: cord-0068356-6km26ilo
authors: Seifer, Lee; Singh, Anita; Csete, Marc
title: LEMIERRE SYNDROME DURING THE COVID-19 PANDEMIC: TIME TO REMEMBER THE "FORGOTTEN DISEASE"?
date: 2021-10-11
journal: Chest
DOI: 10.1016/j.chest.2021.07.332
sha: f12d0a14318e05721dfe844b7ffe8856c2064f2f
doc_id: 68356
cord_uid: 6km26ilo

nan

Lemierre Syndrome is a dangerous complication of pharyngitis resulting in septic thrombophlebitis of the internal jugular vein and usually septic pulmonary emboli. Recognition of this diagnosis requires a high index of suspicion, especially amidst the COVID-19 pandemic in which pharyngitis may be the presenting symptom.

A 34-year-old woman with thalassemia minor presented with worsening dyspnea for 5 days. She tested positive for SARS-CoV-2 10 days prior and her symptoms included sore throat, right lateral neck pain, dry cough, and pleuritic chest pain. She was afebrile, tachycardic, and tachypneic with an O2 saturation of 89% on room air. Physical exam revealed labored breathing and rales in the lung bases, without erythema or exudates in the oropharynx. Labs were notable for a positive SARS-CoV-2 RNA test, WBC of 16k, platelets of 38k, ferritin of 761, CRP of 31, D-dimer of 1.76, and a procalcitonin of 24. CXR revealed diffuse airspace opacities with bilateral pleural effusions. The patient received remdesivir, methylprednisolone, prophylactic enoxaparin, and ceftriaxone for concerns of a superimposed bacterial pneumonia. After 24 hours of inoculation, blood cultures grew Streptococcus Anginosus, a subgroup of viridans streptococci. CT chest showed cavitary lesions and scattered ground-glass opacities with bilateral loculated effusions; thus, superimposed right-sided endocarditis was suspected. However, on day 4, blood cultures grew Fusobacterium Necrogenes leading to the final diagnosis of Lemierre syndrome. The patient received IV ceftriaxone and metronidazole for 4 weeks and then Augmentin for an additional 2 weeks. DISCUSSION: We report the first described case of suspected Lemierre syndrome in a patient with acute COVID-19. With an incidence of 3.6 cases per million compounded by a mortality rate of 9%, the "Forgotten Disease" is rare but potentially devastating. Like COVID-19, the pathogen responsible for Lemierre syndrome induces thrombosis potentially resulting in pulmonary emboli. Although anticoagulation persists as part of the standard of care for patients hospitalized with COVID-19, its role in Lemierre syndrome remains unclear. Some authors advocate for anticoagulation only in those with an underlying hypercoagulable state or with evidence of thrombus progression. Both the efficacy of anticoagulation and whether underlying thrombophilia predisposes patients to develop Lemierre syndrome remain areas of uncertainty.

CONCLUSIONS: Lemierre syndrome should be considered in any young patient deteriorating following pharyngitis. As with COVID-19, the course of Lemierre syndrome may present with respiratory symptoms and rapidly progress to disseminated disease. The endothelial injury and thrombosis induced by COVID-19 may enable bacterial flora with a portal of entry to circulation and facilitate the anaerobes' thrombotic cascade potentiating Lemierre syndrome.

Lemierre's Syndrome and Other Disseminated Fusobacterium Necrophorum Infections in Denmark: a Prospective Epidemiological and Clinical Survey

Lemierre's Syndrome and Risk for Hypercoagulation

A Unique Case of Lemierre Syndrome Associated with Thrombophilia in an Adult and the Role of Anticoagulation